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Obesity is an energy-rich condition associated with overnutrition, which impairs systemic metabolic homeostasis and elicits
stress. It also activates an inflammatory process in metabolically active sites, such as white adipose tissue, liver, and immune
cells. As consequence, increased circulating levels of proinflammatory cytokines, hormone-like molecules, and other inflammatory
markers are induced. This determines a chronic active inflammatory condition, associated with the development of the obesity-
related inflammatory diseases. This paper describes the role of adipose tissue and the biological eﬀects of many adipokines in these
diseases.
1. Introduction
Obesity may be considered as the result of a positive
energy balance in conditions of energy excess. Correlated
with economic, social, and lifestyle changes, it represents
a common condition of diﬀerent populations living in
environments characterised by abundant calorie-rich food
and low physical activity [1]. Hence, obesity is rapidly
arriving at epidemic proportions in many parts of world
and is becoming one of the major public health problems.
More than 1 billion individuals are overweight and more
than 300 million worldwide subjects can be classified as obese
(with body mass index (BMI) of 30 kg/m2 or higher) [1].
More than two thirds of American population is overweight,
a common condition of other Western populations [2]. In
particular, the highest frequency of obesity is observed in
the United States, Europe and the Middle East and the
lowest in sub-Saharan Africa and East Asia [3]. In these
parts of world, this condition is very alarming, because it
occurs in children and adolescents [4, 5]. Hence, the current
obesity may be only considered the “tip of the iceberg”,
which will see young subjects develop the typical age-related
diseases, because obesity predisposes to a variety of age-
related inflammatory diseases, including insulin resistance
(IR), type 2 diabetes, atherosclerosis and its complications,
fatty liver diseases, osteoarthritis, rheumatoid arthritis, and
cancer [6]. The obesity state is, indeed, characterized by what
has been called “low-grade systemic inflammation”, induced
by diﬀerent inflammatory mediators, as demonstrated for
the first time by Hotamisligil et al. in 1993 [7].
The growing evidence on the obesity and the associated
pathologies has led to understand the role of adipose
tissue as an active potential participant in controlling
the physiological and pathological processes. To date, the
adipose tissue is considered as an endocrine organ able to
mediate biological eﬀects on metabolism and inflammation,
contributing to the maintenance of energy homeostasis
and, probably, pathogenesis of obesity-related metabolic and
inflammatory complications [8].
This review describes the role of adipose tissue and
evidences the biological eﬀects and clinical significance of
many adipokines in obesity-related inflammatory diseases.
1.1. Adipose Tissue: Heterogeneity and Functions. Adipose
tissue is vital for the life of mammals. It represents the major
source of fatty acids (FFA) in the postprandial fasting state
for energy use and heat production [9]. Two types of adipose
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tissue are present in mammals: white adipose tissue (WAT)
and brown adipose tissue (BAT) [9]. They have not only
diﬀerent functions, but also a diﬀerent cellular composition
and localization [9].
WAT constitutes the major component of body’s adipose
tissue, provides most of the total body fat and is the
source of FFA, used as energy substrates for the generation
through oxidative phosphorylation of adenosine triphos-
phate (ATP) high-energy bonds [9]. WAT is dispersed
in diﬀerent anatomic body’s sites. Its major depots are
intraabdominal around the omentum, intestines and peri-
renal areas, and subcutaneous in the buttocks, thighs and
abdomen [9]. Hence, it is possible to identify several
local WAT subgroups, including visceral, muscle, epicardial,
perivascular and kidney. Furthermore, WAT seems to have
two key functions, as recently demonstrated by Worzniak et
al. and Juge-Aubry et al. [8, 10]. It is involved in the control
of the metabolism through energy homeostasis, adipocyte
diﬀerentiation, and insulin sensitivity. Besides, it aﬀects
inflammation, through a control mechanism mediated by
antiinflammatory molecules and the activation of anti-
inflammatory metabolic and immune pathways [8, 10].
In addition, each local WAT subgroups have specialised
roles.
Its excessive accumulation in these body’s sites might
arise and determine the development of obesity and the
obesity-related diseases. Much common is the WAT excess
in the upper parts of body, the so-called “android obesity”
or “central obesity”, which represents a strong risk factor
for some inflammatory pathologies [11]. The WAT excess in
other lower body’s sites gives rise to the so-called “gynoid
obesity” with no metabolic complications [9, 11].
To understand the diﬀerent WAT distribution and its
diﬀerent link with metabolic and inflammatory complica-
tions, several theories have been advanced. Among these,
two major theories, not mutually exclusive, have been
considered. The first is based on the anatomy of central
obesity and its capacity to drain FFA and inflammatory
mediators into the portal circulation, where they can act
preferentially on the liver to aﬀect metabolism [9]. The
second considers cell biology and diﬀerent properties of WAT
cells linked with a major or minor risk to develop metabolic
and inflammatory diseases [12]. Significant diﬀerences in
expression of several genes between the diﬀerent body’s
deposits of WAT in both rodents and human have been
detected [13–15]. Interestingly, a diﬀerent mediator profile
has also been observed between visceral and peripheral WAT.
This should seem to clarify the link between central obesity
and metabolic complications. Besides, it also evidences
the heterogeneity in nature and kind of WAT cells [9].
Several types of cells constitute WAT: mature adipocytes
and a variety of other cells (i.e., preadipocytes, fibroblasts,
endothelial cells, and macrophages), usually grouped and
described as the “stroma vascular fraction” [9, 11, 16]. The
adipocytes, preadipocytes, and macrophages have metabolic
and inflammatory functions, which render WAT able to
release several mediators with diﬀerent biological eﬀects
in the WAT itself or other tissues, acting in paracrine or
endocrine way [8, 10, 16–20]. In particular, the macrophages
are responsible for the circulating levels of specific inflam-
matory molecules, determining the “low-grade” chronic
obesity-related inflammation [8, 11, 16, 17, 21].
Unlike WAT, BAT provides energy expenditure from
nonoxidative phosphorylation in form of heat largely for
cold adaptation [22]. The uncoupling of phosphorylation in
BAT is due to the activity of uncoupling protein-1, expressed
on the internal mitochondrial membrane, which by creating
a proton leak exhausts the electrochemical gradient needed
for oxidative phosphorylation. As consequence, BAT aﬀects
energy use by producing heat from uncoupled oxidative
phosphorylation [22]. Unlike WAT, BAT also presents a
smaller number of fat cells, which have richer vascular
supplies with more abundant mitochondrial chromogens,
responsible for the brown colour [22]. BAT with a richer
vascular supply responds more rapidly to sympathetic
nervous system (SNS) stimulation, which then elicits heat
production, rather than ATP production, from nonshivering
cold adaptive thermogenesis [22]. Hence, BAT shows a
diﬀerent function respect to WAT, and, in most mammals,
it is responsible of the heat for fever, the arousal state
from hibernation and cold-induced-thermogenesis [22]. In
humans, BAT is diﬃcult to find postnatally [22]. However,
the positron emission tomography has clearly shown in adult
humans metabolically active BAT depots in cervical, supr-
aclavicular, axillary and paraventral body’s regions. These
depots can be induced in response to cold and SNS activation
[22–24]. This highlights BAT as a potential relevant target for
both pharmacological and gene expression manipulation to
combat human obesity [23, 24].
1.2. Fat Remodelling and Regulation of Energy Homeostasis.
To understand the potential mechanisms involved in energy-
rich condition under overnutrition, it is necessary to known
the processes of energy homeostasis. Adequate body fat and
energy homeostasis are ensured through a dynamic process
of fat remodelling, without excessive weight gain or loss [22].
Conditions of increased appetite and food intake determine
a positive energy balance with weight gain [22]. In contrast,
satiety limits food consumption determining a negative
energy balance and weight loss [22]. This process is mediated
through hypothalamic neuropeptide regulation of appetite
and satiety [22]. Energy expenditure is regulated by central
and autonomic nervous systems, which achieve a balanced
energy homeostasis depending on physiological needs [25].
Hence, conditions of more energy expenditure determine
WAT lipolysis and the consequent augment of FFA, or, con-
versely, less energy expenditure states allow an increased fat
storage [22]. This is controlled by parasympathetic nervous
system (PNS) and SNS. PNS facilitates the fat storage and
decreases the peripheral energy use [26]. SNS stimulates
lipolysis, by increasing the release of FFA for increased
energy expenditure [27]. Both WAT and BAT have SNS
innervations and β3 adrenergic receptors. BAT responds to
cold-induced SNS activity with increased production of heat
from uncoupled oxidative phosphorylation [27, 28]. WAT
stimulated by upregulated SNS activity in response to cold
increases the thermogenesis from oxidative phosphorylation
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of FFA within liver, muscle and fat cells, which is increased in
obesity [27].
Thus, energy homeostasis is achieved by balancing food
intake with energy use. Conditions of increased calorie intake
associated with decreased energy use induce obesity. In obese
conditions, BAT mass and function are strongly decreased
[22]. Obese individuals who are heat intolerant are less able
to dissipate heat from both WAT and BAT [22].
2. Obesity and Inflammation: Causes,
Mechanisms and Consequences
A regulated interaction between metabolic and immunity
system exists [29]. Both over and undernutrition condi-
tions influence metabolism and immune functions [30,
31]. Malnutrition conditions can suppress immune system
and increase susceptibility to infections [30, 31]. Obesity,
an energy-rich condition associated with overnutrition,
impairs systemic metabolic homeostasis and elicits stress
[29]. Stress has been especially linked to development of
visceral obesity [29]. An inflammatory process is simul-
taneously activated by increased WAT mass in metaboli-
cally active sites, such as WAT itself, liver and immune
cells [11, 16–18, 20]. This response determines a strong
increase in circulating levels of proinflammatory cytokines,
hormone-like molecules and other inflammatory markers,
collectively defined “adipokines” [8, 18, 19]. To counteract
the obesity-related stress, hypothalamic-pituitary-adrenal
axis and central and peripheral components of autonomic
nervous system are activated [32]. Under stress condi-
tions they induce physiological responses. Chronic obesity-
related stress induces a prolongation of these adaptive
responses. This leads to an increased level of glucocorticoid,
a steroid hormone able also to induce the development
and diﬀerentiation of preadipocytes, favouring consequently
the further increase of WAT mass [33]. On the other
hand, the secretion of pro-inflammatory cytokines by WAT
may act as additional chronic stimulus for activation of
hypothalamic-pituitary-adrenal axis. Hence, a vicious cycle
between metabolic and immune responses in obesity state is
promoted, inducing a chronic active inflammatory condition
able to determine the onset of obesity-related pathologies
[29, 31].
The causes and mechanisms involved in obesity-induced
inflammatory state are not fully understood, even if the link
between inflammation and obesity has been indicated by
epidemiological studies from 1950s onwards. The discovery
of the production of proinflammatory cytokines in the WAT,
such as tumour necrosis factor (TNF)-α, and TNF-α capacity
to regulate insulin action has systemically also represented a
driving force in this field [7].
Today, current opinion proposes that, under nor-
mal WAT conditions, adipocytes store lipids and regulate
metabolic homeostasis, and resident tissue macrophages,
with polarization essentially of M2 type, release anti-
inflammatory cytokines [21]. M2 macrophages produce
arginase (enzyme involved in the inhibition of nitric
oxide synthase, iNOS) and IL-10, IL-1Ra anti-inflammatory
cytokines [21, 34, 35]. In contrast, M1 type macrophages
have a specific surface marker (CD11c+) and release iNOS
and classical proinflammatory cytokines [21, 34, 35]. Normal
WAT is, so, characterised by an anti-inflammatory tissue
milieu able to protect from the development of obesity-
related inflammation and IR, most likely also due to activity
of members of peroxisome proliferator-activated receptor-
(PPAR)s (particularly PPAR-α and -γ) and liver X receptor-
(LXR) families, molecules involved in nutrient transport and
metabolism and able to antagonize inflammatory activity
[36, 37]. To contribute to this physiological WAT condition
is a new adipokine, the lipocalin-2 (LCN2). LCN2 upregu-
lates PPARγ, increases the release of adiponectin and also
antagonizes TNF-α eﬀects on inflammatory and metabolic
gene expression in adipocytes and macrophages. Conversely,
knocking down LCN2 expression, using lentiviral shRNA
gene silencing, results in decreased expression of PPARγ
and its target genes, adiponectin, and leptin. Hence, LCN2,
seems to act as an antagonist to the eﬀect of inflammatory
molecules on inflammation and secretion of adipokines [38].
In obesity conditions, WAT becomes inflamed, state
determined by a crosstalk principally between adipocytes and
macrophages [8, 16, 21]. The obesity-related inflammatory
state occurs in several sequential stages, characterised by
a cellular WAT composition remodelling. An increase in
number (hyperplasia) and size (hypertrophy) of adipocytes,
a macrophage infiltration, and fibrosis characterise WAT
in obesity human conditions [39–45]. Adipocyte hyper-
trophy is induced by two factors: increased fat storage in
fully diﬀerentiated adipocytes and increased expression of
proinflammatory mediators [43–45]. On the other hand,
hypertrophic adipocytes shift the immune balance towards
the production of proinflammatory molecules [40, 46–
49]. The shift in the cytokines profile creates a tissue
milieu responsible of the strong modification of the WAT
macrophages pool from activated M2 type to classically-
activated M1 type [21, 34, 35, 40, 46–49]. In addition, the
M1 macrophage WAT pool considerably increases because
of the diﬀerentiation of monocytes recruited in inflamed
WAT. In obese WAT, macrophages also aggregate in “crown-
like structures” constituted by necrotic-like adipocytes and
adipocyte cellular fragments [46–51]. An increased infiltra-
tion of macrophages, indeed, occurs in the inflamed WAT,
preferentially into visceral WAT, which contributes of the
WAT inflammation state and its exacerbation [10, 16, 17, 20,
21, 34, 35, 46, 47]. Several chemokines, chemokine receptors,
and adhesion molecules are involved in this process [50]. It
seems also to be directly correlated with both hyperplasia
and hypertrophy of adipocytes and inflammatory mediator
production [10, 16, 17, 20, 21]. However, the mechanisms
responsible for attracting monocyte/macrophage cells and
their entry into the fat mass remain unclear. The group
of Sengene`s et al. has recently evidenced a key role of
endothelial cells in the control of the inflammatory WAT
process. It has also been described the potential involvement
of WAT-endothelial cells as further factors involved in the
regulation of macrophage phenotype in the “inflamed fat
tissue” [48]. Inflammatory WAT cytokine profile seems to
be responsible of the activation of endothelial cells and their
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expression of a series of adhesion molecules involved in the
recruitment of monocyte/macrophages. Furthermore, it has
been demonstrated an association between angiogenesis and
adipogenesis [52].
Concerning the shift of cytokines (M2/M1 cytokine
profile), the exact mechanisms involved have not yet been
clarified [21, 34, 35, 40, 46–49]. It has been proposed that
adipocytes from diﬀerent body depots show diﬀerences in
their inflammatory phenotype, with visceral fat characterised
by more inflammatory phenotype respect to subcutaneous
fat, as discussed above [9, 12]. Besides, the increased obesity-
associated preadipocyte diﬀerentiation process seems also
to contribute to this inflammatory cytokine profile [9, 12].
However, human WAT macrophage subsets show no strict
M1 or M2 polarization, as recently demonstrated by Bourlier
et al. [40] and Zeyda et al. [21].
Furthermore, another characteristic phenomenon, the
local hypoxia induced by hypoperfusion due to rapid fat
mass expanding seems to contribute to WAT inflammatory
state [53–55]. Adipose hypoxia, indeed, induces the release
of proinflammatory mediators [53–55].
However, on the whole, these observations give no a
clear dissection of the cause and eﬀect relationship between
obesity and inflammation. On the other hand, it has,
recently, been demonstrated that increased adipose tissue
mass is not essentially related with WAT inflammation
state, as observed in two studies performed in adiponectin
transgenic mice and lipocalin-2 knockout mice [56–58].
This suggests that, although obesity is directly linked to
inflammation, the specific role of adipokines and related
pathways might be clarified.
3. Molecules Produced by WAT: “Adipokines”
WAT releases hundreds of biologically active molecules, the
“adipokines”, including more than 50 cytokines, chemokines,
hormone-like factors and other mediators [8, 18, 19]
Not exclusively produced by WAT cells, these media-
tors are released by other diﬀerent body’s tissues and
organs with functions unrelated to those within WAT
[18, 19]. Adipokines aﬀect appetite and satiety, glucose
and lipid metabolism, blood pressure regulation, inflam-
mation and immune functions [8, 18, 19]. Precisely,
they work as a network to regulate inflammation, insulin
action, and glucose metabolism locally and systemically.
This adipokine/cytokine networking system is altered in
obesity, contributing to inflammation state and impaired
adipocyte metabolism. However, how adipokines and
cytokines coordinately regulate obesity-related inflammation
and metabolism is not clearly understood [8, 18, 19].
Diﬀerent mechanisms are involved in the adipokine
secretion. The production of inflammatory adipokines (such
as proinflammatory cytokines, chemokines, molecules asso-
ciated with thrombosis, and hypertension, etc.) seems to
be complex and involves several inflammatory pathways,
activated by both extracellular mediators and intracellular
stressors. Among extracellular factors, the FFA are the
primary inductors of these pathways [59]. In human obesity,
they are chronically elevated (by determining lipotoxicity),
because of blunted incapacity of insulin to inhibit the
lipolysis and the excessive consumption of dietary lipids [60].
Innate immunity receptors, such as Toll-like receptor
(TLR)-4 and -2, are expressed in WAT (particularly by
adipocytes, preadipocytes, macrophages, and endothelial
cells) and are involved in this obesity-related inflammatory
process. Their expression is increased and induced in obese
subjects [60, 61]. FFA and other molecules produced by
hypoxic conditions during obesity activate these receptors,
particularly TLR4 [60, 61]. Lipopolysaccharide (LPS) is
another factor able to activate TLR4 [62]. A key source of LPS
is the gut microbiota [59]. It is continually produced within
the gut by death of Gram-negative bacteria and is absorbed
into intestinal capillaries to be transported by lipoproteins
[63, 64]. On the other hand, it has been observed that a high-
fat diet given to mice increases the proportion of gut LPS
[63, 64]. These data indicate the gut microbiotia may have
an important role in the induction of chronic obesity-related
inflammation [63].
Hence, FFA, particularly via TLR4 induce the pro-
inflammatory adipokine production in adipocytes [65, 66].
FFA also activate macrophages, referentially of the CD11c+
subset, through the TLR4 pathway, exacerbating their pro-
inflammatory activity [66–68]. Furthermore, a paracrine
loop between hypertrophied adipocytes and macrophages
has been evidenced, able to induce a vicious circle of
inflammatory exacerbated WAT state [68]. This paracrine
loop involves FFA and TNF-α. As a result, macrophages
secrete the pro-inflammatory TNF-α. TNF-α in turn, acting
particularly on TNF-α receptor 1 subtype, induces inflam-
matory changes in hypertrophied adipocytes as well as
increased release of FFA [68]. In addition, this paracrine
cross-talk could be further improved in obese subjects
through the adipocyte hyperresponsiveness to TNF-α and
subsequent hyperactivation of inflammatory pathway [52].
FFA may also be active on the adipocyte in an autocrine way
to evoke an inflammatory state and chemokine/adipokine
overproduction at least in part via TLR4 [69]. This autocrine
mechanism has been proposed to be an initial event of the
inflammatory WAT cascade, but this issue is still controver-
sial.
In obese WAT the cells and the intracellular organelles
are also exposed to increased stress, mainly as a result
of metabolic overload [31]. In particular, mitochondria
and the endoplasmic reticulum appear to be the most
sensitive organelles to metabolic stressors [70]. In addition,
the development of hypoxic conditions in the expanded
WAT during obesity results in an increased production of
reactive oxygen species and the corresponding development
of oxidative stress [70].
Signals mediated by both extracellular and intracellular
factors culminate predominantly in the activation, princi-
pally via TLR4 receptor, of NF-κB transcriptional factor,
responsible of the production of inflammatory mediators, as
well as the direct inhibition of insulin signaling [60, 61, 71].
Hence, NF-κB pathway represents the crucial and major
factor responsible of obesity-induced inflammation. To
amplify inflammation-mediated inhibition of insulin action
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Figure 1: A common yet preventable risk factor for these multi-
factorial age-related diseases is the visceral obesity. Metabolic syn-
drome is also associated with obesity. It assembles some abnormal-
ities, including insulin resistance, hyperinsulinemia, hypertension,
and dysplipidemia, all risk factors directly associated with both type
2 diabetes and cardiovascular diseases.
are also other pathways, such as those mediated through the
suppressor of cytokine signaling-(SOCS)-proteins and iNOS
[72, 73].
In contrast, anti-inflammatory adipokine molecules
seem to be released through the activation of diﬀerent
transcription factors induced via PPAR-γ and LXR receptors,
as mentioned above [36–38]. In conditions of overnutrition,
fatty acid-binding proteins, FABPs, likely sequester ligands
of PPAR-α and LXRs and induce no activation of these
transcription factors [74].
In this paper, the attention has particularly been focussed
on adipokines involved in the obesity-related inflammatory
diseases. The biological eﬀects of metabolic and inflamma-
tory adipokines are reported in Tables 1 and 2.
4. Role of Visceral Obesity in Ageing and
Obesity-Related Inflammatory Diseases
Several pathologies are associated with obesity, such as type
2 diabetes and cardiovascular diseases (CVD) [6]. More
recently, the obesity-related risk has also been extended to
cancer, including prostate, breast, liver, kidney, colon, ovar-
ian and endometrial cancers [75–81]. The obesity-related
diseases are characterised by inflammatory pathophysiology
induced by several risk factors (environmental stressors,
genetic factors, etc.) and an onset generally correlated with
ageing process. Epidemiological studies have revealed that
a common yet preventable risk factor for these diseases is
the increase of the visceral fat, a characterised hallmark of
ageing in humans (Figure 1) [8, 11, 12, 82]. Using either waist
circumference and/or waist-to-hip ratio as a proxy of visceral
obesity, the role of visceral fat as stronger risk factor for these
diseases, than BMI or other fat depots, has been confirmed.
Obesity-related risk is not only limited to these diseases,
but also to cognitive decline, Alzheimer’s disease (AD) and
disability, as recently demonstrated [6, 83–85].
Recent evidence also reports an association of obesity
with increased risk of disease specific and all-cause mortality,
and with a reduced life expectancy [82]. For example,
the group of Fontaine reported that Caucasian men and
women with a BMI > 40 and age range 20–29 years,
could expect a reduction in remaining years of life expected
by approximately 6 and 12 years, respectively [86]. An
increment of mortality and a reduction of life expectancy
correlated with obesity, especially in old subjects, has been,
indeed, proposed. On the other hand, obesity, and precisely
visceral obesity, seems to accelerate ageing process. It has
been demonstrated that obese women have telomeres of
240 bp shorter lean women of a similar age [87]. In view of
the hypothesis that telomere length in vivo represents cellular
turnover and exposure to oxidative and inflammatory dam-
age, this diﬀerence in telomere length between being lean and
being obese might correspond to 8.8 years of ageing [87].
The increased evidence on visceral obesity, as a stronger
predictor of these diseases, has led to assess the mortality
risk correlated with abdominal obesity [88–90]. In 2008,
a large European study reported that both general (BMI)
and abdominal adiposity (waist circumference; waist-to-hip
ratio) are strong predictors of mortality risk [91]. However,
the importance of visceral obesity was most remarkable
among persons with a low BMI [91].
The question of visceral fat, as factor capable of reducing
life expectancy, has been recently clarified in an animal
model study [92]. The extrapolation of its data in humans
suggests the key role of visceral fat and the possibility through
its depletion to favour the survival and, hence, longevity,
as demonstrated in calorie restriction rats [92]. In human
beings, its beneficial eﬀects might be greater, since humans
visceral fat depots have direct portal access and, so, a greater
potential to harm the liver [82, 92]. This has recently led
Huﬀman and Barzilai to hypothesise the presumed link
of visceral fat with both age-related diseases and lifespan.
Accumulation of visceral fat represents a greater risk for
the development of IR and other processes of metabolic
syndrome than other fat depots due to its anatomical
location, high lipolytic rate and secretion of inflammatory
adipokines. This determines some specific perturbations to
tissue including hepatic IR, impaired glucose uptake by
skeletal muscle and increased basal lipolytic rate and WAT
free fatty acid release. The long-term consequences are an
increased risk for obesity-related inflammatory diseases and
mortality and a reduced lifespan [82].
4.1. Evolutionary Speculations about the Link between Obesity
andObesity-Related Diseases. The association of obesity with
obesity-related inflammatory diseases might be explained
through evolutionary speculations. It is appropriate, hence,
to consider the fundamental biological necessities for the
survival of an organism: (1) the ability to resist to starvation
and (2) to evoke an eﬃcient immune response to pathogens.
To this aim, several metabolic and immune pathways
and nutrient- and pathogen-sensing systems have been
selected and evolutionarily conserved throughout species.
The metabolic systems have been selected to assure energy
eﬃciency through the storage of excess calories particularly
under intermittent food uptake conditions. In contrast,
under continuous overnutritional conditions, these systems
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Table 1: Adipokines involved in energy balance/metabolism.
Name Cell type expression Biological eﬀects
Leptin: no glycosylated peptide hormone of
16 kDa encoded by the obese (ob) gene,
discovered in 1994 by Zhang et al. [18, 19]
Adipocytes: synthesis
induced by food intake,
eating-related hormones,
energy status, and sex
hormones (being inhibited
by testosterone and
increased by ovarian sex
steroids) and several
proinflammatory
mediators (being increased
or inhibited by
proinflmmatory cytokines
with acute or chronic
action)
Satiety signal with direct eﬀects on the
hypothalamus; stimulates lipolysis; inhibits
lipogenesis; improves insulin sensitivity; increases
glucose metabolism; and stimulates fatty acid
oxidation. Hence, leptin operates as adipostatin
and general inductor of energy reserve, being
involved in glucose metabolism, synthesis of
glucocorticoids. However, it is also known its
involvement in other processes, such as the
proliferation of lymphocytes (particularly CD4+)
and induction of Th1 response, cytokine
production, phagocytosis, and regulation of
hypothalamic-pituitary-adrenal-axis,
reproduction, angiogenesis, and oxidative stress.
Collectively, these functions consent to define
leptin as a cytokine-like hormone characterised by
pleiotropic propriety [18, 19]
Adiponectin: a protein of 30-kDa with a
structural homology with collagen VIII and
X and complement factor C1q. Once
synthesised, it forms trimers which then
oligomirize to constitute polymers
composed of 4 to 6 trimers. Trimers,
hexamers, and high molecular weight
(HMW) 12 to-18 mers of adiponectin are
present in circulation [18, 19]
Adipocytes Increases fatty acid oxidation with reduction in
plasma fatty acid levels; decreases plasma glucose
levels; increases insulin sensitivity;
anti-inflammatory, antioxidant, antiatherogenic
and anticancer properties through the inhibition
TNF-α-mediated of NF-κB pathway
Resistin: a member of resistin-like molecule
(RELMs) family, called “resistin” for its
capacity to induce IR in mice. Resistin is
also known as member of molecule “found
in inflammatory zone” (FIZZ)—family
characterised by four members,
characterised by a conserved 11-cysteine
pattern at the C terminus. Resistin or
FIZZ-3 was initially discovered in mice
[18, 19]
Adipocytes and M2
macrophages
Induces severe hepatic insulin resistance-increased
rate of glucose production in rat (increased resistin
plasma concentrations in diet-induced obese mice,
but reduced mRNA levels in WAT of obese rodents;
stimulates lipolysis); functions controversial in
humans
Adipsin: (also called in human complement
factor D46) is a rate-limiting enzyme in the
alternative pathway of complement
activation [18, 19]
Adipocytes and M2
macrophages
Stimulates triglyceride storage, inhibits lipolysis
Apelin: a bioactive peptide, representing
endogenous ligand of orphan
G-protein-coupled receptor, APJ, homolog
to angiotensin II receptor [18, 19]
Adipocytes and stromal
vascular cells (in particular
macrophages)
Reduces food intake (?); inhibits glucose-induced
insulin secretion; antagonize angiotensin II eﬀects
in atherosclerosis inducing NO production and
inhibiting angiotensin II cellular signaling (?
However, there are contrasting literature data).
Visfatin: An insulin mimetic adipokine
recently discovered and released prevalently
by visceral WAT. Visfatin is also identical to
pre-B-cell colony-enhancing factor (PBEF),
a cytokine that has been observed increased
both in bronchoalveolar lavage fluid in
animal models and in neutrophils in septic
conditions Under endotoxin stimulation,
PBEF/visfatin is produced by neutrophils,
inhibiting neutrophil apoptosis [18, 19]
Adipocytes Under endotoxin
stimulation,
PBEF/visfatin/NAMPT is
also produced by
neutrophils, inhibiting
neutrophil apoptosis
Insulin-mimetic eﬀects; hypoglycaemic eﬀects by
stimulating glucose uptake; promotes insulin
sensitivity; proadipogenic and lipogenic action. It
also induces chemotaxis and the production of
IL-1β, TNF-α, and IL6 in CD14+ monocytes and
increases proliferative responses in lymphocytes. In
addition, visfatin seems to have a nicotinamide
adenine dinucleotide (NAD) biosynthetic activity
in pancreatic β cells [49]. Hence, visfatin acts as
nicotinamide phosphoribosyltransferase (Nampt),
the rate-limiting enzyme that converts
nicotinamide (a form of vitamin B3) to
nicotinamide mononucleotide (NMN), and a NAD
precursor [51].
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Table 1: Continued.
Name Cell type expression Biological eﬀects
Vaspin: a serpin (serine protease inhibitor)
[18, 19]
Adipocytes Improves insulin sensitivity; suppresses the
production of resistin, leptin, and TNF-α
Omentin: a secretory protein, recently
identified as a new adipokine It is codified
by two genes (1 and 2) [18, 19]
Stromal vascular cells (in
particular macrophages)
Enhances insulin-stimulated glucose transport in
subcutaneous as well as omental adipocytes;
modulation of insulin action
Lipocalin-2 (LCN2), also known as 24p3 or
neutrophil gelatinase-associated lipocalin
(NGAL): a recently indentified adipokine of
the superfamily of lipocalins. It is a 25kDa
secretory glycoprotein, originally identified
in mouse kidney cells and human
neutrophil granules. In adipose tissue, it is
highly expressed in vivo and in vitro, and its
secretion is regulated by the activation of
inflammation and infection [58].
Adipocytes and
macrophages, but also
neutrophils, hepatic and
kidney cells
Has diﬀerent actions, such as apoptosis and innate
immunity; aﬀects glucose metabolism and insulin
sensitivity; seems to have dual eﬀects on
inflammation: pro- and anti-inflammatory eﬀects.
So, increased levels of LCN2 in obesity and IR may
constitute a protective mechanism against
inflammation [58]
Retinol binding protein-4 (RBP4): this
protein belongs a the superfamily of
lipocalins. And it is a specific carrier for
retinol in the blood [58].
Adipocytes Promotes IR and the type 2 diabetes [58]
induce a fat excess, as no advantageous state associated with
the onset of several chronic disorders, such as obesity and
its complications. At the same time, the necessity to defend
against the infections has determined the selection of strong
immune components, particularly induced by the epidemic
and pandemic infections [93, 94]. The combination of these
eﬃcient systems has likely created a fundamental biological
instrument able to store energy and to evoke immune-
inflammatory responses. Its existence is showed by the
several pathways with metabolic and immune functions
evolved from common and ancestral units. A characteristic
ancestral unit is the body fat of Drosophila, having metabolic
functions and an intimate control of immune responses. It
has given rise after about 600 million years to homologous
mammalian tissues, such as haematopoietic and immune
systems, liver and adipose tissue [95–98]. These mammalian
tissues have conserved their development heritage and
show metabolic and immune cellular components with an
architectural organization able to have immediate access into
blood vessels. Hence, they have continuous and dynamic
interactions with other important metabolic and immune
sites, such as pancreas. This contributes to understand the
mechanisms involved in metabolic diseases, such as type
2 diabetes [99]. They have common regulatory molecular
pathways and pathogen-sensing systems able to regulate both
metabolic and immune functions. Characteristic example is
the TLR4-NF-κβ pathway, evolved by Drosophila homolo-
gous Toll and able to mediate eﬃcient immune responses
also metabolically or nutritionally induced and lipid-related
pathways able to respond to the energy necessities of partic-
ular conditions, such as during the induction of immune or
inflammatory response [66, 93, 95].
These observations suggest a fine balance between
metabolic and immune systems. Its dysfunction is dangerous
and responsible of the development of some diseases.
In particular, overnutritional conditions, fruit of current
nutritional habits and lifestyles of most modern Western
populations, are responsible of the development of the
obesity-related inflammatory diseases [100].
In the light of these observations and suggestions, we
described the role of adipokines in the pathophysiology of
obesity-related inflammatory diseases.
5. Adipokines and Obesity-Related
Inflammatory Diseases
5.1. Metabolic Syndrome and Cardiovascular Diseases. The
term “Metabolic syndrome” (MS) assembles some abnor-
malities, including visceral obesity, dyslipidemia, hypergly-
caemia and hypertension. The criteria to define MS have
been established by International Diabetes Federation (IDF)
[97]. In the IDF consensus, MS is defined by the presence
of visceral obesity plus two of the described components
[101, 102]. The presence of any two of the four next
components is also required: elevated circulating levels of
triglycerides, reduced levels of HDL-cholesterol, high blood
pressure and impaired fasting glycaemia [101, 102]. The
IDF eventually recommends other criteria to diagnose MS,
such as increased levels of circulating inflammatory and/or
thrombotic markers (CRP, SAA, TNF-α, IL-6, and PAI)
or reduced levels of anti-inflammatory molecules, such as
adiponectin. This syndrome is currently considered one of
the major public health challenges, as demonstrated by two
large studies performed, respectively, in 2.600 American
individuals (age range 25–64 years) and 3000 European
subjects (age range∼55 years) [103]. In the two populations,
the 25%–40% and 30% (of an Italian cohort), respectively,
were aﬀected by MS [103].
The MS pathophysiology is complex and diﬀerent
adipokines seem to be involved. Several reports have demon-
strated in MS patients increased IL-6 levels related to BMI
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Table 2: Adipocytokines, chemokines, vascular proteins, and other proinflammatory markers produced in WAT and systemic sites and
involved in the inflammatory-obesity responses.
Name Cell type expression Biological eﬀects
Proinflammatory cytokines
IL-6: one the crucial pro-inflammatory
mediator, secreted by several body’s cell types
(monocytes, adipocytes, endothelial cells,
fibroblasts, etc.) [10, 11]
Stromal vascular fraction:
the 90% WAT IL-6
production comes from
these cells. Under the
obesity conditions, both
adipocytes and
macrophages are the
principal responsible of
WAT derived IL-6,
although the stimuli for the
induction of IL-6
production seem to be
diﬀerent.
Decreases insulin and leptin signaling; induces the
hepatic release of acute-phase proteins, such as
C-reactive protein, and the hypothalamic induction
of fever; seems to have a controversial role in insulin
resistance: it seems to impair hepatic signaling
through the increased expression of SOCS-3
impairing the phosphorylation of insulin receptor
substrate 1 (IRS-1) and the transcription factor
PKB/Akt. Furthermore, down-regulates the
expression of IRS-1 and Glucose transporter 4. In
addition, SOCS-3 has the capacity to bind and to
inhibit the insulin receptor and to induce the
proteosomal degradation of IRS proteins. IL-6 also
induces fatty acid oxidation and lipolysis [102]
TNF-α: another remarkable proinflammatory
cytokine [10, 11]
Adipocytes and M1
macrophages
Induces IR and increases lipolysis in adipocytes;
decreases adiponectin and increases IL-6 expression.
TNF-α should also play an atherogenic role inducing
an increased expression of adhesion molecules in
vascular wall, increasing the scavenger receptor class
A expression and oxidised LDL uptake in
macrophages and stimulating their infiltration in
vascular wall
IL-1: Another pro-inflammatory cytokine,
member of IL-1 family (IL-1α, IL-1β, and
IL-1Ra) [10, 11]
M1 Macrophages Induces fever, acute-phase proteins, proliferation of
fibroblasts, smooth muscle cells, and production of
antibodies, cytokines, and angiogenesis, metastasis,
and cartilage breakdown. It also appears to aﬀect
glucose homeostasis and insulin sensitivity through
central and peripheral mechanisms. IL-1 also
mediates direct eﬀects on adipocytes, decreasing the
expression and the activity of LPL, increasing
lypolisis and aﬀecting adipocyte diﬀerentiation
through inhibition of PPAR receptors
Anti-inflammatory cytokines
IL-1Ra: a cytokine antagonist able to limit
inflammation, competing with IL-1 for binding
to its receptor without inducing a signal [10, 11]
M2 macrophages and
hepatic cells as an
acute-phase protein under
systemic inflammation
stimuli
Produced in response to stress and by M2
macrophages to create an anti-inflammatory WAT
milieu in physiological condition. High serum levels
of IL-1Ra are associated with insulin resistance
IL-10: an anti-inflammatory cytokine inhibiting
the production of several proinflammatory
cytokines (IL-1, IL-6, and TNF-α), chemokines
and increasing the levels of anti-inflammatory
cytokine such as IL-1Ra [10, 11]
Adipocytes and M2
macrophages
Produced by M2 macrophages to create an
anti-inflammatory WAT milieu in physiological
condition. In obesity, high levels of IL-10 have been
observed
Proinflammatory chemokines
IL-8: a proinflammatory chemokine [10, 11] Stromal vascular cells Induces the migration of diﬀerent cell blood types,
such as monocytes, particularly in inflammatory
conditions. In obesity, high IL-8 levels have been
observed and increased levels of IL-8 mRNA have
been detected principally in visceral WAT. They seem
correlated to fat mass and BMI
Mcp-1 (CCL2): key chemokine involved in
recruitment of monocytes/macrophages and in
monocyte tissue infiltration. Its levels
conspicuously increase under IL-1, TNF-α, and
LPS stimuli, while under normal conditions are
undetectable [10, 11]
Adipocytes/M1 macrophages Increases lipolysis and leptin secretion;
decreasesinsulin-stimulated glucose uptake;
(increased plasmaconcentrations in obesity; disturbs
insulin sensitivity)
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Table 2: Continued.
Name Cell type expression Biological eﬀects
Adipokines associated with thrombosis and
hypertension and other inflammatory markers
PAI-1: a serine protease inhibitor (serpin) with
the physiological function to inhibit
plasminogen activation [10, 11]
Stromal vascular cells with
visceral WAT secretion more
elevated than subcutaneous
WAT
Inhibits plasminogen activation. Elevated PAI-1
levels determine a pathological condition
characterised by hypofibrinolysis and a
prothrombotic state It aﬀects cellular matrix
degradation, smooth muscle cell migration and
angiogenesis, determining the development of
atherosclerosis. In obese conditions, PAI-1 seems to
contribute directly to obesity complications, such as
atherothrombosis, insulin resistance and type 2
diabetes
Angiotensinogen (AGT): the precursor of
vasoactive peptide angiotensin II (Ang II), a
component of vasoconstrictor renin-angiotensin
system (RAS) [10, 11]
Stromal vascular cells and
adipocytes, with visceral
WAT secretion more elevated
than subcutaneous WA
Linked to vascular inflammation (increased
plasmalevels in obesity) and increased blood
pressure
C-reactive protein (CRP): one of the acute-phase
proteins in inflammation. It is a member of
short pentraxins produced in the liver in
response of IL-6 [10, 11]
Hepatic cells, human mature
adipocytes, but not
preadipocytes, under
inflammatory stimuli,
including lipopolysaccharide
(LPS), TNF-α, and resistin
Endothelial dysfunction, adhesion molecules
expression, Tissue factor production,
PAI-1upregulation, mononuclear cells recruitment,
adhesion, activation and cytokine production, ROS
and MMPs production, uptake of oxLDL, foam cells
formation, proliferation, migration, ROS
production, MMPs, MCP-1, and iNOS expression
Serum amyloid protein (SAA): constitute a family
of lipoproteins involved in the transport of
cholesterol and the host defence alarm system
[10, 11].
Hepatic cells, adipocytes SAA are not only inflammatory markers induced by
IL-6, but also represent inflammatory mediators able
to induce inflammatory events in leucocytes. In
particular, SAA proteins can mediate chemotaxis of
monocytes into WAT with hypertrophic adipocytes
and at the same time to increase the expression of
adhesion molecules in endothelial WAT cells. SSA
proteins seem responsible of increased incidence of
cardiovascular diseases in obese individuals. They
are able to interact with high-density lipoprotein
(HDL)-receptor competing with HDL, and thereby
inhibit the HDL-mediated clearance of cholesterol,
increasing the development of atherosclerotic
lesions.
[100, 101]. In particular, the involvement of IL-6 in IR
and its complications has been evidenced, even if its role
remains controversial [104–106]. The mechanisms involved,
indeed, are not fully clear. However, IL-6 seems to induce IR,
impairing hepatic signaling through the increased expression
of SOCS-3 and aﬀecting the phosphorylation of insulin
receptor substrate 1 (IRS-1) and the transcription factor
PKB/Akt [104–106]. SOCS-3 has the capacity to bind and to
inhibit the insulin receptor and to induce the proteosomal
degradation of IRS proteins. Using 3T3-L1 adipocytes, it
has been demonstrated the IL-6 capacity to induce partial
resistance in insulin-dependent glucose uptake through
down-regulation of the phosphorylation of IRS-1 and the
expression of IRS-1 and Glucose transporter 4 (GLUT–4)
[10, 66–68, 107]. Furthermore, in 3T3-L1 adipocytes, IL-6
reduces the activity of lipoprotein lipase-LPL [52, 107].
TNF-α seems also involved in MS. High TNF-α levels
have been observed in MS subjects [100]. The relationship
between high levels of TNF-α and MS is related to the
TNF-α capacity to induce a c-Jun NH2-terminal kinase to
mediate a serine phosphorylation of IRS-1. This determines
the inhibition of normal tyrosine phosphorylation of IRS-1
and downstream insulin signaling [104].
Furthermore, in obesity, an overexpression of
angiotensinogen and an increased activity of vasoconstrictor
renin-angiotensin system have been demonstrated [108].
This phenomenon seems also to contribute to the alteration
of insulin sensitivity and to increase the incidence of type 2
diabetes and MS [109].
Recent evidence also demonstrates the association of
elevated levels of systemic inflammatory molecules, such as
SAA and CRP, with type 2 diabetes and MS [110].
It has also been demonstrated the role of leptin in
the MS pathophysiology. It evokes a condition, which
aﬀects insulin sensitivity and induces IR. In particular,
leptin induces in hypothalamus the release of “anorexigenic
peptides” (i.e., proopiomelanocortin and corticotrophin-
releasing hormone) and, reciprocally the inhibition of
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“orexigenic peptides” (i.e., neuropeptide Y and agouti-
related protein), thereby limiting food intake [111]. In
obesity conditions, hypothalamic resistance to leptin has
been found and ascribed to reduced transport of leptin
across the blood-brain barrier and to increased levels of
SOCS-3 and ER stress, which inhibit leptin signaling [112,
113]. This evokes profound changes in energy balance and
hormone production via the hypothalamus, analogous to
those induced in response to fasting. Hence, a response of
adaptation to low levels of leptin is induced, determining
overfeeding and inhibition of energy expenditure, thyroid
and reproductive hormones, and immunity. Hypothetically,
this response may be evolved as a protection against the
threat of starvation [111]. In obese subjects, these changes
determine reduced energy expenditure and to regain weight,
associated with lipid accumulation [114]. Ectopic lipid
storage (in liver, epicardial, and muscle fat) is also induced
in obese conditions because of leptin resistance, which may
in turn further impair insulin sensitivity [52]. Like leptin
eﬀects, another adipokine, resistin, seems to mediate IR.
Its role may be evidenced in rodents, as suggested by an
interesting theory [18, 19, 52]. However, successive studies in
both rodents and humans have reported contradictory data
[18, 19].
An interesting role in the MS pathophysiology and
its complications seems mediated through a more recent
discovery adipokine, visfatin, which its plasma levels are
correlated to lipid metabolism and inflammatory response
[18, 115]. It mediates a nicotinamide adenine dinucleotide
(NAD) biosynthetic activity in pancreatic β cells [116].
Hence, visfatin acts as nicotinamide phosphoribosyltrans-
ferase (Nampt), the rate-limiting enzyme that converts
nicotinamide (a form of vitamin B3) to nicotinamide
mononucleotide (NMN), a NAD precursor [112]. It has
been reported a decline with advanced age of Nampt-
mediated systemic NAD biosynthesis, able to determine a
reduced sirtuin-1 activity. This mechanism might contribute
to decreased function of pancreatic β cells in aged subjects
[117].
Furthermore, another adipokine recently identified with
a key role in insulin resistance is LCN-2, as demonstrated in
LCN-2 knockout mice [57].
In contrast, a protective role of adiponectin against MS
(and the other obesity-related pathologies) has recently been
demonstrated [118]. This molecule reduces M1 macrophage
functions, by inhibiting phagocyte activity and release of IL-
6 and TNF-α, and increases the IL-10 and IL-1Ra production
in adipocytes and macrophages [10, 18, 19]. Apelin also
reduces the MS risk. In obesity, increased plasma and WAT
levels of apelin have been detected [18, 19]. TNF-α seems to
be the responsible of these increased levels both in plasma
and WAT [18, 19]. This molecule seems to reestablish glucose
tolerance and increased glucose utilization, as demonstrated
in a mice study [119]. These data should suggest the
use of this molecule in the treatment of IR. Studies on
animal models particularly in the apelin-knockout mice have
evidenced that loss of apelin determines heart diseases in
response to pressure overload [120].
Growing evidence highlights the link of systemic-obesity
inflammatory state with both CVD onset and CVD risk
[110, 121]. Several studies have demonstrated a link between
WAT excess and CVD mortality in young (particularly
in adolescents) and old subjects [110, 121]. Furthermore,
a relationship between WAT excess and coronary artery
calcium (a marker of coronary atherosclerosis) measurement
has been reported [122]. Imaging approaches have also been
confirmed this association [122]. How obesity determines
the CVD development, it is until now not clearly understood.
Complex and numerous obesity-mediated mechanisms are
identified, as well as the CVD risk obesity-related factors
(including hypertension, IR and dyslipidemia). Systemic
and WAT adipokines seem also to aﬀect vessel wall, by
determining adverse eﬀects [110, 121, 122]. Precisely, proin-
flammatory cytokines, hormone-like molecules and other
WAT adipokines act in the liver, causing changes in the pro-
duction and the release of lipoproteins, coagulation factors
and inflammatory molecules [110, 121, 122]. In particular,
they induce an increase of very-low-density lipoprotein,
apolipoprotein B (apoB), and triglyceride secretion [123].
These liver-released molecules act on endothelial, arterial
smooth muscle and macrophages cells, by inducing athero-
genic eﬀects on the vessel wall through the regulation of their
gene expression and functions [110, 121, 122]. In addition,
visceral fat seems to be particularly involved in the activation
of these pathways [122, 123].
Interestingly, among adipokines, leptin mediates diﬀer-
ent eﬀects on cells of vessel wall. It evokes on endothelial cells
oxidative stress, increased production of adhesion molecules
and chemokines and proliferation [110, 121, 122]. For
example, an increased blood release of MCP-1 in obese
condition has been observed. It seems to increase the
number of CD11c+ monocytes, favouring the binding of
monocytes/macrophages to the vessel wall [124]. Acting
also on smooth muscle cells, leptin induces their migration,
proliferation, and hypertrophy [110, 121, 122]. It also
induces a further activation and cytokine production of
macrophages, neutrophils, and T cells and it seems also
involved in the calcification of cells of vessel wall and the
thrombosis through the increase of platelet aggregation [110,
121, 122]. These eﬀects are also indirectly mediate of leptin
through leptin resistance (mentioned above).
Resistin induces similar eﬀects to those of leptin. In
human, levels of resistin seem to be positively associated with
coronary atherosclerosis [125]. It induces on endothelial cells
an increased expression of adhesion molecules, proinflam-
matory cytokines, and pentraxin [125].On smooth muscle
cells, it evokes their migration. An increased expression of
CD36 on macrophages seems to be also mediated by resistin,
facilitating lipid accumulation and formation of foam cells
[126, 127]. On macrophages it also mediates an increased
production of proinflammatory cytokines, through via TLR4
and NF-κB pathway [128].
Among the adipokines of recent discovery, visfatin, and
apelin seem to have a key role in the CVD pathophysiology.
Visfatin has a key role in plaque destabilization, associated
with its increased expression in macrophages of human
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unstable carotid and coronary atherosclerosis [129]. In con-
trast, its plasma levels are negatively associated with vascular
endothelial function [130]. Paradoxical data reported by van
der Veer et al. have demonstrated that visfatin can, however,
prolong the life of human smooth muscle cells [131].
Unlike visfatin, apelin is associated with a positive
hemodynamic profile and has positive inotropic eﬀects in
normal and failing rat hearts and in isolated cardiomyocytes
[132–134]. In patients aﬀected by single atrial fibrillation and
chronic heart failure, reduced plasma apelin levels have been
found [135, 136]. In vessel wall and cardiovascular tissue of
rats, apelin production seems to be upregulated by hypoxia
and ischemic cardiomyopathy, likely as a compensatory
mechanism [137, 138].
In contrast, adiponectin seems to induce beneficial
eﬀects. Its levels are positively correlated with HDL levels,
and negatively with triglyceride levels, IR, and systemic
circulating inflammatory markers [139, 140]. Furthermore,
a negative correlation between adiponectin and coronary
artery calcium has been observed [141]. It also promotes
several anti-atherogenic and anti-inflammatory eﬀects on
vessel cells: it downregulates the expression of adhesion
molecules on endothelial cells [142]; it decreases endothelial
oxidative stress and increases eNOS activity [143]; in smooth
muscle cells it inhibits proliferation by suppressing the
release of growth factors [144]; and in macrophages it
reduces lipid accumulation and the expression of scavenger
receptors [145].
Furthermore, CRP, usually increased in CDV, has athero-
genic eﬀects on vessel wall [146, 147]. This atherogenic
eﬀect is also increased by other WAT molecules, such as
AGT, angiotensin-converting enzyme and PAI-1. AGT II
has vasoconstrictive actions and also promotes systemic
inflammation [121, 122]; AGT contributes to the activation
of renin-angiotensin system (RAS) and both these molecules
induce a hypertensive response [117, 118]. PAI-1 seems to be
involved in atherothrombosis [121, 122].
5.2. Obesity and Alzheimer Disease. AD is a heterogeneous
and progressive neurodegenerative disease which in Western
societies mainly accounts for clinical dementia [148]. The
AD prevalence is below 1% in individuals aged 60 years,
but shows an almost exponential increase with age, so that,
in the Western world, in people aged 85 years or older the
prevalence is between 24% and 33%. It prevalence is expected
to quadruple by the year 2047 in the United Stated [149].
There is currently no cure for AD and its pathogenesis
remains the subject of many theories involving genetic as
well as environmental factors. Recent mounting evidence has
been supposed the involvement of modifiable risk factors
in AD neurodegeneration, such as lifestyle factors. Among
these, obesity represents an AD risk factor. Several potential
mechanisms seem to link obesity with AD: hyperglycemia,
advanced glycosylation products, adipokine action, and the
influence of obesity on vascular risk and cerebrovascular
disease.
IR and hyperinsulinemia seem to represent the key causes
for the development of some age-related diseases, such as AD
[6]. Recently, a role of insulin in AD neurodegeneration has
been reported [150]. Precisely, insulin, crossing the blood
brain barrier from periphery to central nervous system,
seems to compete with Aβ amyloid peptide for insulin
degrading enzyme (IDE) in the brain, including also the
hippocampus [151]. In contrast, insulin produced in the
brain seems to have an advantageous eﬀect on amyloid
clearance [152]. Opposing eﬀects seem to be mediated by
conditions of peripheral hyperinsulinemia. They seem to
determine the inhibition of brain insulin production, which
in turn results in impaired amyloid clearance and a higher
AD risk [152]. These data suggest that reducing peripheral
hyperinsulinemia and increasing brain insulin levels, ben-
eficial eﬀects might be attained on AD neurodegeneration.
Therapy strategies able to reduce blood insulin levels in
humans have been demonstrated to aﬀect cognition and
levels of amyloid β in the cerebrospinal fluid, supporting the
potential direct role of insulin in AD [153, 154].
Hyperglycemia seems to be also responsible of the
increased levels of advanced glycosylation end products
(AGEs). An increased glycation of amyloid β has been
demonstrated to improve its aggregation in vitro. Further-
more, AGE receptors seem also to be specific cell surface
receptors for amyloid β, thus potentially facilitating neuronal
damage [155].
Concerning the role of adipokines in AD, it is not clear
whether their involvement in the AD pathophysiology are
direct or associated with IR and hyperinsulinemia. On the
other hand, systemic inflammation seems to be a risk AD
factor [156]. Some studies have proposed a direct action of
adipokines in AD neurodegeneration. For example, leptin
seems to aﬀect CA1 nucleus of the hippocampus [157].
Several eﬀects of leptin on the brain development and
potentially on brain health in cognition and ageing have
also been observed. This evidences the capacity of leptin to
aﬀect the function of the hypothalamus and learning and
memory processes controlled by the hippocampus [157].
Leptin receptors have been observed in the hippocampus,
hypothalamus, amygdala, cerebellum, and brain stem, sup-
porting its capacity to mediate regulatory mechanisms [157].
A direct interaction between leptin and adiponectin and
hypothalamic nuclei has been evidenced [157]. However,
other roles of leptin and related adipose-derived factors in
the AD brain are not clear [158]. Fasting plasma leptin has
been inversely correlated with grey matter volume in areas
of the brain in which obese have reduced grey matter in
comparison with lean individuals [159].
Another potential link between obesity and AD is cere-
brovascular disease (CD). CD and stroke are associated with
a higher AD risk [160–162]. Their direct action on amyloid
cascade, however, is not clear. Current opinion proposes
CD as additional brain damage to amyloid neurotoxicity
[161, 162]. However, RAS system seems to link obesity with
CD and AD. RAS system regulates the blood pressure. Both
human brain and WAT express RAS, with WAT RAS involved
in adipocyte growth, diﬀerentiation and metabolism [163,
164]. The RAS activation takes place when blood pressure is
low. In this state, the formation of Angiotensin II is evoked.
Its interaction with specific receptors induces the activation
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of RAS, determining an increased of blood pressure. In the
brain, angiotensin II continues its conversion to angiotensin
IV, which enhances learning and memory in animal models
[165, 166].
Another potential mechanism theoretically involved in
AD neurodegeneration is hypercholesterolemia. To this aim,
some prospective studies have examined total LDL and HDL
cholesterol levels as possible risk AD factors. Contrasting
data have been reported. The association of cholesterol with
dementia may vary depending upon when cholesterol is
measured in the life-span and/or relative to the course of
disease. High cholesterol may be a risk factor if measured
in midlife many years before clinical onset, but then as the
disease pathology progresses, cholesterol levels may fall such
that it appears that high cholesterol is protective. Two Finnish
studies have, indeed, observed that high total cholesterol
levels in mid-life are associated with an increased risk of
AD more than 20 years later [167, 168]. In contrast, no
association has been found cross-sectionally [164]. Two
studies each with more than 25 years of follow-up, did
not find an association between mid-life total and HDL
cholesterol and incident AD [169, 170]. Three other studies
in elderly populations also did not find associations between
LDL and/or HDL cholesterol and incident AD after follow-
ups of 2 years and 7 years [171, 172]. In fact, one of
these studies reported an inverse association between total
cholesterol and AD, such that those in the lowest quartile
had the greatest risk [168]. Similarly, higher cholesterol levels
have been reported to be associated with a reduced risk for
AD [173, 174].
5.3. Obesity and Prostate Cancer. Prostate cancer (PC) is the
most common cancer in Western elderly male populations.
Its incidence increases rapidly in men over 50 years of age
[175]. The development of PC is based on the interaction
between genetic factors and the host exposure to environ-
mental factors, such as infectious agents, dietary carcinogens
and hormonal imbalances. In this complex situation, chronic
inflammation seems to play a key role [176–181].
As reported above, the risk associated with obesity has
also been extended to several malignancies. Its role in
PC aetiology is less clear [182]. Data on the association
between obesity and PC incidence are inconsistent, and in
some studies obesity is associated with an increase in risk
of low-grade tumours. The reasons of these contrasting
results may be due, in part, to variation of the methods of
anthropometric measurement, such as BMI and the waist-
to-hip ratio. However, a recent study has revealed visceral
fat accumulation as specific risk factor for PC [6, 76].
More consistently, it has recently been suggested that obesity
reduces the risk of nonaggressive PC disease and increases the
risk of aggressive PC disease [182]. Hence, it is possible that
rather than increasing the absolute risk of PC development,
obesity may be associated with the progression of latent
or microscopic PC to clinically significant and metastatic
PC. Furthermore, the diﬀerential eﬀects of obesity on PC
subtypes suggest aetiological heterogeneity of these tumours
and complex interaction between androgen metabolism
and several putative risk factors, including IR, diabetes,
inflammation, and genetic susceptibility, on PC risk [182].
The molecular mechanisms liking obesity and PC patho-
physiology are numerous and occur at several levels. A first
mechanism seems correlated to sex steroid pathways [182].
However, the relationship between sex steroid hormones
and obesity is complex and biological processes involved
are unclear. Current opinion suggests a decline in men
of serum testosterone levels in obese conditions [183]. In
addition, increased peripheral aromatization of androgens
to oestrogens, correlated with fat overload, is also involved
in the decline of androgens [182]. On the other hand,
it is well-documented an age-related decrease of serum
testosterone levels [183]. However, testosterone seems to
induce diﬀerential eﬀects. Recent data have shown that
higher serum levels of total testosterone are associated with
a reduced risk of high-grade PC, but with an increased
risk of low-grade PC [184]. This emphasizes the complex
relationship between obesity and serum sex steroid, and their
diﬀerential eﬀect on PC, but further supports the diﬀerential
eﬀect of obesity on PC subtypes.
Another mechanism is correlated to capacity of obesity to
modify the production of other hormones, such as insulin-
like growth factors (IGFs), having mitogenic properties. An
additional mechanism is mediated by adipokines. It has
been reported that adipokines may modulate the biological
behaviour of PC cells. In particular, leptin, IL-6 and TNF-α
seem able to enhance tumour growth [185]. The association
between systemic leptin levels and PC has been analysed in
several studies. The obtained data have reported a positive
association between high leptin levels and the risk of large
volume prostatic tumours [185]. Stattin et al. have evidenced
an association between moderately high leptin levels and
later PC development [185]. Furthermore, the association
between leptin and PC seems particularly confined to male
subjects having a with waist-to-hip ratio >0.87. This datum
evidences the interaction of leptin with other molecules
correlated with abdominal obesity, such as sex hormones
bioavailability and IGF-1 levels [185]. Another study has
demonstrated in a relatively small number of PC patients
an association between serum leptin levels and prostate
specific antigen and Gleason score [185]. In vitro studies
have evidenced a role of leptin in PC carcinogenesis and
its capacity to promote the proliferation of androgen-
independent PC cell lines [185]. In vitro, it has been
also observed the capacity of leptin to induce vascular
endothelial cell proliferation, and in vivo angiogenesis, key
processes involved in cancer progression, invasion, and
metastasis [185]. The proliferative response of PC cells to
leptin has been shown to involve intracellular signaling
molecules such as phosphatidyl-inositol 3-kinase (PI3-K)
and c-Jun NH2-terminal kinase (JNK) [185]. Alterations
in these signaling pathways are not only critical in pro-
cesses of prostate carcinogenesis and malignant transfor-
mation, but also important in obesity, diabetes, and IR
[185].
High serum IL-6 levels are also associated with PC [185].
A role of IL-6 has been suggested in the early stages of
prostate carcinogenesis [185].
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Diﬀerence eﬀects seem to be mediated by the other
adipokines, such as adiponectin proposed as an anticancer
factor in some tumours, PC included [181]. In support
of this, significant lower levels of adiponectin have been
observed in PC patients respect to subjects with benign pro-
static hyperplasia or healthy controls [185]. This study also
evidences a negative association between plasma adiponectin
and Gleason score and PC stage. Adiponectin receptors have
been found in both benign and malignant human prostate
tissue [185]. In the LNCaP and PC3 PC cell lines, it has
been evidenced that androgens, oestrogen, TNF-α, leptin
and adiponectin seem all to act and regulate adiponectin
receptors. These results might to suggest a complex role of
adiponectin in the PC carcinogenesis, mediated through its
interaction with sex hormones and cytokines.
6. Conclusions: Possible Strategies for New
Therapeutic Treatments for Obesity-Related
Inflammatory Diseases
Human visceral obesity represents one of the major risk
factors for obesity-related diseases. Possible strategies for
the prevention and the development of new therapeutic
treatments are, hence, crucial medical challenge.
In researching potential strategies, crucial questions
remains open. It is not clear whether eﬀectively obesity
inflammatory state determines a metabolic deterioration.
Furthermore, it is not also clear whether inflammation can
simply be considered a state activated by altered nutrient
clearance.
To date, the literature evidence leads to consider the
regulator molecular pathways, evolutionary well-conserved
and able to control the evocation of immune responses and
metabolic processes and, as possible ways for therapeutic
approaches. However, their selection is diﬃcult, as well as
their manipulation with possible pharmacological agents
to interfere with immune and metabolic systems, without
to determine severe consequences on key mechanisms of
organism. A possible candidate might be the TLR4-NF-κB
pathway, having the role of hub in the induction of both
metabolic and inflammatory processes, as described. Hence,
its antagonists might be used to block the release of metabolic
and inflammatory adipokines. On the other hand, TLR4-NF-
κB pathway has a key role in the pathophysiology of age-
related inflammatory diseases, such as CVD, AD, and PC, as
we have recently demonstrated [62, 176, 186, 187].
Other possible pathways might be the lipid-related
pathways, such as PPAR-α and LXR pathways. It is already
established with success that the use of thiazolidinediones
or statins (ligands of this pathway and insulin sensitising
compounds) is able to regulate lipid metabolism and to
induce anti-inflammatory eﬀects.
Another possible way for the development of possi-
ble pharmacological approaches for inflammatory obesity-
related diseases might involve the adipokines, even if several
their eﬀects and functions remain unclear. In this case, the
strategy might hypothetically have as aim the control of
the bioavailability of some adipokines, such as leptin and
adiponectin, in obese conditions. Exogenous administration
of adiponectin might counteract the consequences of obesity
state, such as leptin-induced inflammation, or activate
its antiatherogenic, vasoprotective and anticancer actions.
Another alternative avenue might be the inhibition of leptin
receptors through monoclonal antibodies or mutant leptin.
Other possible targets might be pro-inflammatory cytokines
and chemokines or their receptors, through the use of their
agonists or monoclonal antibodies.
In summary, these observations emphasize the necessity
to discover the metabolic and immune pathways, including
also the molecules involved in metabolic and pathogen
sensing systems, involved in the delicate balance of interplay
between metabolic and immune systems. This might be
useful to clarify and to understand the mechanisms induced
and to open possible ways for therapeutic approaches able
to enhance the capacity of endogenous molecules to prevent
stress and inflammatory responses induced by metabolic
signals.
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